Anti-scl-70

Autoimmunity

Volumn 38, Issue 1, 2005, Pages 65-72

  Basu, Dhiman ^a   Reveille, John D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Anti Scl 70; Autoantibodies; Scleroderma; Topoisomerase I

Indexed keywords

SCL 70 ANTIBODY;

ANAMNESIS; ANTIBODY DETECTION; CONNECTIVE TISSUE DISEASE; DATA ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; IMMUNODIFFUSION; IMMUNOPRECIPITATION; INFORMATION RETRIEVAL; LUNG FIBROSIS; MEDICAL LITERATURE; PATIENT CARE; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SKIN DISEASE; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; DIAGNOSIS, DIFFERENTIAL; HISTORY, 20TH CENTURY; HUMANS; IMMUNOASSAY; NUCLEAR PROTEINS; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 17144407607     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930400022947     Document Type: Review

References (74)

1. Feghali-Bostwick C, Medsger Jr, TA, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003;48:1956-1963.
2. Mayes MD, Reveille JD. Epidemiology, Demographics, and Genetics of Systemic Sclerosis. In: Clements PJ, editors. Systemic Sclerosis. 2003. In press.
3. Fennell RHJ, Rodnan GP, Vazquez JJ. Variability of tissue-localizing properties of serum from patients with different disease states. Lab Investig 1962;11:24-31.
4. Beck JS, Anderson JR, Gray KG, Rowell NR. Antinuclear and precipitating autoantibodies in progressive systemic sclerosis. Lancet 1963;2:1188-1190.
5. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514-10522.
6. Shero JH, Bordwell B, Earnshaw WC. High titers of autoantibodies to topoisomerase I (SCL-70) in sera from scleroderma patients. Science 1986;14:737-740.
7. Maul GG, French BT, van Venrooij WJ, Jimenez SA. Topoisomerase I identified by scleroderma 70 antisera: Enrichment of topoisomerase I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci 1986;83:5145-5149.
8. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980;23:617-625.
9. Reveille JD, Solomon DH. American college of Rheumatology, Ad Hoc Committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70 and nucleolar antibodies. Arthritis Rheum 2003;49:399-412.
10. Aeschlimann A, Meyer O, Bougeois P, Haim T, Belmatoug N, Palazzo E, Kahn MF. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations. Ann Rheum Dis 1989;48:992-997.
11. Hildebrandt S, Weiner E, Senecal JL, Noell S, Daniels L, Earnshaw WC, Rothfield NF. The IgG, IgM and IgA isotypes of antitopoisomerase-I and anticentromere autoantibodies. Arthritis Rheum 1990;33:724-727.
12. Tsay GJ, Fann RH, Hwang J. Specificity of anti-Scl-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus. J Rheumatol 1990;17:1314-1319.
13. Cram DS, Fisicaro N, McNeilage LJ, Coopel RL, Harrison LC. Antibody specificities of Thai and Australian scleroderma sera with topoisomerase I recombinant fusion proteins. J Immunol 1993;151:6872-6881.
14. Seelig HP, Schroter H, Ehrfeld H, Renz M. Autoantibodies against topoisomerase I detected with the natural enzyme and overlapping recombinant peptides. J Immunol Methods 1993;165:241-252, Oct. 15.
15. Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Rothfield NF, Smeenk R, Takasaki Y, van Venrooij WJ, Wiik A, Wilson M, Koziol JA. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999;42:455-464.
16. Weiner ES, Earnshaw WC, Senecal JL, Bordwell B, Johnson P, Rothfield NF. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. Arthritis Rheum 1988;31:378-385.
17. Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Ziminski C, Alarcon GS, Luggen ME, Polisson RP, Willkens RF, Yarboro C, McDuffie FC, Ward JR. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 1991;18:1340-1343.
18. Catoggio LJ, Bernstein RM, Black CM, Hughes GRV, Maddison PJ. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983;42:23-27.
19. Catoggio LJ, Skinner RP, Maddison PJ. Frequency and clinical significance of anticentromere and anti Scl-70 antibodies in an English connective tissue disease population. Rheum Int 1983;3:19-21.
20. McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989;32:54-60.
21. Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA. Antinuclear antibodies in scleroderma, mixed connective tissue disease and primary Raynaud's phenomenon [published erratum appears in Clinphenomenon. Clin Rheum 1998;7:80-86, [published erratum appears in Clin Rheum Jun;7(2) (1998) 277].
22. Fritzler MJ, Kinsella JD, Garbutt E. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980;69:520-526.
23. Bunn CC, Denton CP, Shi-wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
24. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH. Scl 70 antibody - a specific marker of systemic sclerosis. Br J Dermatol 1986;115:393-401.
25. Tuffanelli DL, McKeon F, Kleinsmith DM, Burnham TK, Kirschner M. Anticentromere and anticentriole antibodies in the scleroderma spectrum. Arch Dermatol 1983;119:560-566.
26. Moutsopoulos HM, Giotaki H, Maddison PJ, Mavridis AC, Drosos AA, Skopouli FN. Antibodies to cellular antigens in Greek patients with autoimmune rheumatic diseases: anti-Ro (SSA) antibody a possible marker of penicillamine-D intolerance. Ann Rheum Dis 1984;43:285-287.
27. Takehara K, Moroi Y, Ishibashi Y. Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol 1985;112:23-33.
28. McHugh NJ, Whyte J, Artlett C, Briggs DC, Stephens CO, Olsen NJ, Gusseva NG, Maddison PJ, Black CM, Welsh K. Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study. Clin Exp Immunol 1994;96:267-274.
29. de Rooij DJ, van de Putte LB, Habets WJ, Verbeek AL, van Venrooij WJ. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Scand J Rheumatol 1988;17:353-364.
30. Hildebrandt S, Weiner ES, Senecal JL, Noell GS, Earnshaw WC, Rothfield NF. Autoantibodies to topoisomerase 1 (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1990;57:399-441.
31. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological associations with RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999;117:395-402.
32. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Results of a multicenter study. Clin Chem 2000;46:1681-1685.
33. Jarzabek-Chorzelska M, Blaszczyk M, Kolacinska-Strasz Z, Jablonska S, Chorzelski T, Maul GG. Are ACA and Scl 70 antibodies mutually exclusive. Br J Dermatol 1990;122:201-208.
34. Bizzaro N, Tonutti E, Villalta D, Bassetti D, Tozzoli R, Manoni F, Pirrone S, Piazza A, Rizzotti P, Pradella M. Sensitivity and specificity of immunological methods for the detection of anti-topoisomeraseI (Scl-70) autoantibodies: Results of a multicenter study. Clin Chem 2000;46:1681-1685, 34.
35. Lopez-Longo FJ, Rodriguez-Mahou M, Escalona-Monge M, Gonzalez CM, Monteagudo I, Carreno-Perez L. Simultaneous identification of various antinuclear antibodies using an automated multiparameter line immunoassay system. Lupus 2003;12:623-629.
36. Spencer-Green G, Alter D, Welch HG. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am J Med 1997;103:242-248, (34).
37. Gussin HA, Ignat P, Varga J, et al. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001 Feb; 44:376-383.
38. Omagari K, Ohba K, Kadokawa Y, Hayashida K, Isomoto H, Takeshima F, Mizuta Y, Murata I, Kohno S. Anti-extractable nuclear antigens (ENA) antibodies in patients with chronic hepatitis C before and after treatment with interferon. Autoimmunity 2003;36:269-273.
39. Ruffatti A, Calligaro A, Ferri C, et al. Association of anti-centromere and anti-Scl 70 antibodies in scleroderma. Report of two cases. J Clin Lab Immunol 1985;16:227-229.
40. Reveille JD, Durban E, MacLeod MJ, Goldstein R, Moreda R, Altman RD, Arnett FC. Association of amino acid sequences in the HLA-DQB1 first domain with the anti-topoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Investig 1992;90:973-980.
41. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 2001 Apr; 30:332-346.
42. Mayes MD, Lacey Jr, JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003 Aug; 48:2246-2255.
43. Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004 May; 43:596-602.
44. Wollersheim H, Thien T, Hoet MH, et al. The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon. Eur J Clin Investig 1989 Dec; 19:535-541.
45. Kallenberg CG, Wouda AA, Hoet MH, et al. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988 Aug; 47:634-641.
46. Steen VD, Powell DL, Medsger Jr, TA, et al. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988 Feb; 31:196-203.
47. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Balt) 2002 Mar; 81:139-153.
48. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 2003 Apr; 42:534-540.
49. Jacobsen S, Halberg P, Ullman S, van Venrooij WJ, Hoier-Madsen M, Wiik A, Petersen J. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol 1998;37:39-45.
50. Kuwana M, kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75-83.
51. Hietarinta M, Ilonen J, Lassila O, Hietaharju A. Association of HLA antigens with anti-Scl-70-antibodies and clinical manifestations of systemic sclerosis (scleroderma). Br J Rheumatol 1994;33:323-326.
52. de Rooij DJ, van de Putte LBA, Habets WJ, van VenRooij WJ. Marker antibodies in scleroderma and polymyositis: clinical associations. Clin Rheum 1989;8:231-237.
53. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological associations with RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999;117:395-402.
54. Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998 Sep; 114:801-807.
55. Cassani F, Tosti A, Bianchi FB, Fusconi M, Selleri L, Bafoni L, Veronesi S, Volta U, Lenzi M, Pisi E. Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies. Clin Exp Rheum 1987;5:23-28.
56. Kane GC, Varga J, Conant EF, Spirn PW, Jimenez S, Fish JE, Kane GC. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent of skin involvement or autoantibody status. Resp Med 1996;90:223-230.
57. Riboldi P, Asero R, Origgi L, Crespi S, Meroni PL, Sguotti C, Sabbadini MG. Antinuclear antibodies in progressive systemic sclerosis. Clin Exp Rheum 1985;3:205-211.
58. Murata I, Takenaka K, Shinohara S, et al. Diversity of myocardial involvement in systemic sclerosis: an 8-year study of 95 Japanese patients. Am Heart J 1998 Jun;135 (6 Pt 1):960-969.
59. Jacobsen S, Ullman S, Shen GQ, et al. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001 Nov; 28:2454-2459.
60. Sulli A, Ghio M, Bezante GP, et al. Blunted coronary flow reserve in systemic sclerosis. Rheumatology (Oxford) 2004 Apr; 43:505-509.
61. Nishijima C, Sato S, Hasegawa M, et al. Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology 2001;40:406-409.
62. Rothfield N, Kurtzman S, Vasques-Abad D, et al. Association of anti-topoisomerase I with cancer. Arthritis Rheum 1992 Jun; 35:724.
63. Derk CT, Sakkas LI, Rasheed M, et al. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol 2003 Sep; 30:1994-1996.
64. Weiner ES, Hildebrandt S, Senecal JL, Daniels L, Noell S, Joyal F, Roussin A, Earnshaw W, Rothfield NF. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. Arthritis Rheum 1991;34:68-77.
65. Vasquez-Abad D, Russell CA, Cusick SM, Earnshaw WC, Rothfield NF. Longitudinal study of anticentromere and antitopoisomerase-1 isotypes. Clin Immunol Immunopathol 1995;74:257-270.
66. Hildebrandt S, Jackh G, Weber S, Peter HH. A long-term longitudinal isotypic study of antitopoisomerase I autoantibodies. Rheumatol Int 1993;12:231-234.
67. Henry PA, Atamas SP, Yurovsky VV, Luzina I, Wigley F, White B. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. Arthritis Rheum 2000;43:2733-2742.
68. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000;43:1074-1084.
69. Hu PQ, Fertig N, Medsger Jr, TA, et al. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003 May; 48:1363-1373.
70. Bell SA, Faust H, Mittermuller J, et al. Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histo-compatibility locus antigen association. Br J Dermatol 1996 May; 134:848-854.
71. Chosidow O, Bagot M, Vernant JP, et al. Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. J Am Acad Dermatol 1992 Jan; 26(1):49-55.
72. Kaufman LD, Varga J, Gomez-Reino JJ, et al. Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome. Demonstration of unique antigen-antibody specificities. Clin Immunol Immunopathol 1995 Aug; 76:115-119.
73. Mackay-Wiggan JM, Cohen DJ, Hardy MA, et al. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003 Jan; 48:55-60.
74. Gambichler T, Paech V, Kreuter A, et al. Nephrogenic fibrosing dermopathy. Clin Exp Dermatol 2004 May; 29:258-260.